Prognostic Immune Biomarkers in HNSCC

Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel

NCT06947668 ·Status: RECRUITING

A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

NCT06793761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Anti-tumor Specific Immune Response in Head and Neck Cancers

NCT02881918 ·Status: UNKNOWN

Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy

NCT03114163 ·Status: COMPLETED

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients

NCT01415674 ·Status: COMPLETED ·Phase: PHASE2

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

NCT07026474 ·Status: RECRUITING ·Phase: PHASE3

Real-World Evidence and Treatment Patterns: Head and Neck Cancer

NCT03157674 ·Status: COMPLETED

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC

NCT03813836 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

NCT03652142 ·Status: UNKNOWN

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

NCT06100497 ·Status: RECRUITING ·Phase: PHASE2

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

NCT04858269 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)

NCT02059668 ·Status: COMPLETED

Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers

NCT04086849 ·Status: COMPLETED

Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma

NCT02775812 ·Status: COMPLETED ·Phase: PHASE1

Pembrolizumab Plus Olaparib in LA-HNSCC

NCT05366166 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

NCT03569436 ·Status: COMPLETED

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

NCT03620123 ·Status: COMPLETED ·Phase: PHASE2

Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas

NCT06236464 ·Status: RECRUITING

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

NCT00768664 ·Status: COMPLETED ·Phase: PHASE2

Effect of Prolonged Nightly Fasting on Immunotherapy Outcomes in HNSCC - Role of Gut Microbiome

NCT05083416 ·Status: COMPLETED ·Phase: NA

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT03386357 ·Status: TERMINATED ·Phase: PHASE2

Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma

NCT03727594 ·Status: UNKNOWN

Immune Response Evaluation to Curative Conventional Therapy

NCT03053661 ·Status: UNKNOWN

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220 ·Status: RECRUITING ·Phase: PHASE3

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05721755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3